Coherus licenses toripalimab rights in Canada to Apotex for $6.25M upfront

Coherus Oncology, Inc.

Upfront payment of $6.25M USD; up to $51.5M CAD in regulatory and sales milestones.
Apotex to pay low double-digit percentage of net sales; Coherus pays Junshi under existing collaboration.
License term: 10 years after first commercial sale, with option to extend for another 10 years.
Apotex may terminate for any reason after notice; agreement ends if Coherus-Junshi collaboration terminates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.